Health Ministry officers confirmed that the Indian drug regulator has granted an Emergency Use Authorization (EUA) for Bharat Biotech’s Covaxin for the age group of 12-18 years.
With Friday’s approval, Bharat Biotech’s Covaxin will develop into the second candidate to be administered to kids above the age of 12 when the federal government takes a remaining determination on introducing COVID-19 vaccination for kids.
On October 12, the Subject Expert Committee (SEC) had really helpful the Drug Controller General of India (DGCI) to grant an Emergency Use Authorization (EUA) for the age group of 2-18 years for Bharat Biotech’s Covaxin. However, the EUA is granted for 12-18 years. In India, the drug regulator has additionally authorised Zydus Cadila’s DNA Covid-19 vaccine for kids above the age of 12 years solely.
,
With inputs from TheIndianEXPRESS
